Full-Time

Territory Business Manager

SpringWorks Therapeutics

SpringWorks Therapeutics

201-500 employees

Clinical-stage precision medicines for cancer

Compensation Overview

$185k - $210k/yr

+ Discretionary Incentive Compensation

Atlanta, GA, USA

Remote

Must reside within the Atlanta, GA territory.

Bachelor's, Master's

Category
Sales & Account Management (1)

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Requirements
  • Bachelor’s degree required (Advanced degree preferred)
  • 7+ years of pharmaceutical and/or biotech experience required
  • 5+ years proven Rare Disease sales experience in the pharmaceutical/healthcare industry with demonstration of successful results
  • Neurology experience– pediatric and adult experience
  • Oncology experience
  • Experience selling in a competitive market
  • Experience in Rare Disease sales
  • Experience with virtual selling and track record of embracing technology
  • In-depth understanding of the Neurology/Oncology landscape and market dynamics is highly desirable
  • Strong expertise in reimbursement and managed care knowledge
  • Possesses high integrity and exceptional work ethic. Fosters mutual trust and respect
  • Strong organizational skills
  • Strong communication both written and verbal
  • A connector and one who thinks and acts as one team
  • Collaborative and curious by nature
  • Embody the Values of SpringWorks Therapeutics to act with empathy and humility to drive a culture that takes ownership and accountability for their individual performance
  • A valid and active driver’s license
  • Position may require domestic travel up to 50% of time
  • Candidate must live within the identified territory
Responsibilities
  • Maintain an expert operating knowledge of all company policies and guidelines including but not limited to those addressing interactions with Healthcare Professionals, compliance and business conduct
  • Ensure compliance with all Company, industry and government laws or regulations including guidelines pertaining to ethical business practices
  • Accountable for overall territory revenue and customer support
  • Achieve short and long-term sales objectives by identifying customer needs and providing solutions to create a professional relationship between the customer and SpringWorks Therapeutics, a healthcare company of Merck KGaA Darmstadt Germany in both the live and virtual setting, as well as, within the community/academic setting respectfully
  • Build relationships with key HCP’s, physician practices, and hospitals/clinics, practice managers across various treatment and academic settings, including major cancer centers
  • Be a territory expert having deep market, customer, product, and competitive insights. Understand the changing healthcare landscape and strategically adapt to succeed in a constantly evolving environment
  • Successfully complete ongoing training and development to include product knowledge, selling skills, goal setting, planning and analysis, use of marketing tools and clinical information and sales competencies
  • Strategically identify and enact ways to appropriately put patients and customers first, demonstrating behaviors and prioritizing those tasks which will enable delivery of medicines to patients with greater speed and increase the ability to help patients’ lives
  • Demonstrate strong critical analytic and planning skills in reviewing data, understanding trends, preparing, communicating applicable plans and embracing the digital platforms/omnichannel strategies
  • Fully participate in field coaching sessions, including receiving guidance, positive reinforcement, and corrective action where needed with a focus on the execution of accounts plans and competency development to ensure revenue targets are met
  • Work collaboratively and manage ongoing communication and tactical coordination with field and HQ colleagues
  • Work to support local/area KOL’s
Desired Qualifications
  • In-depth understanding of the Neurology/Oncology landscape and market dynamics is highly desirable
  • Experience with digital tools and platforms beyond traditional selling approaches is desirable
  • Willingness to travel beyond 50% travel if required by the role
  • Experience mentoring or leading sales teams is desirable
  • Prior experience within Merck KGaA Darmstadt Germany ecosystem or similar corporate culture is desirable
SpringWorks Therapeutics

SpringWorks Therapeutics

View

SpringWorks Therapeutics is a clinical-stage biopharmaceutical company that develops precision medicines for patients with rare diseases and cancer. Its approach is to tailor therapies based on the genetic and molecular profile of a disease, aiming to improve treatment effectiveness and safety for underserved patient groups. The company advances drug candidates through clinical trials (such as Phase 1b and 2) and pursues partnerships with other pharmaceutical companies to acquire, develop, and commercialize therapies. Unlike broader, non-targeted programs, SpringWorks focuses on niche patient populations defined by genetic profiles and collaborates on development and commercialization, broadening access to targeted treatments. The company’s goal is to bring targeted therapies to market that address unmet medical needs in oncology and rare diseases, improving outcomes for patients with specific genetic conditions.

Company Size

201-500

Company Stage

IPO

Headquarters

New York City, New York

Founded

2017

Get referred to SpringWorks Therapeutics

See people who can refer or advise you

Simplify Jobs

Simplify's Take

What believers are saying

  • Merck KGaA expects the SpringWorks deal to boost earnings per share by 2027.
  • European approval for mirdametinib broadens reimbursement and physician adoption across major EU markets.
  • Nirogacestat's long-term DeFi data in August 2025 strengthened durability and commercial credibility.

What critics are saying

  • SpringWorks lost independence on July 1, 2025; Merck KGaA now owns every asset.
  • Revenue depends heavily on nirogacestat and mirdametinib; a safety issue would crush the franchise.
  • Pimicotinib and other pipeline bets face crowded rare-oncology competition and execution delays through 2027.

What makes SpringWorks Therapeutics unique

  • Nirogacestat became the first FDA-approved desmoid tumor therapy in November 2023.
  • Mirdametinib won EU conditional approval on July 18, 2025, spanning adults and children.
  • SpringWorks built rare-tumor expertise before Merck KGaA closed the acquisition on July 1, 2025.

Help us improve and share your feedback! Did you find this helpful?

Benefits

Health Insurance

Dental Insurance

Vision Insurance

Life Insurance

Disability Insurance

Paid Vacation

Paid Sick Leave

Professional Development Budget

Flexible Work Hours

Remote Work Options

Growth & Insights and Company News

Headcount

6 month growth

1%

1 year growth

4%

2 year growth

4%
AD HOC NEWS
May 21st, 2026
SpringWorks Therapeutics agrees to cash merger with $3.52B market cap desmoid tumor franchise

SpringWorks Therapeutics has completed a cash merger, according to a Robinhood corporate actions update from May 2026. The Nasdaq-listed biotech, which traded at $46.99 with a market capitalisation of approximately $3.52 billion as of mid-May, focuses on developing targeted therapies for rare diseases and oncology. The company's lead asset is nirogacestat, a gamma-secretase inhibitor for desmoid tumours, addressing significant unmet medical needs in this rare soft-tissue condition. SpringWorks also develops mirdametinib, a MEK inhibitor targeting neurofibromatosis type 1 plexiform neurofibromas. As a clinical-stage company, SpringWorks currently reports negative earnings, reflecting ongoing development costs typical of pre-commercial biotechnology firms. The company operates within the US-centred biotech ecosystem, with most clinical trials and regulatory interactions based in the United States.

AllSci
Mar 17th, 2026
R1 Therapeutics launches with oversubscribed USD 77.5m Series A.

R1 Therapeutics launches with oversubscribed USD 77.5m Series A. March 17, 2026 R1 Therapeutics, a clinical-stage biopharmaceutical company headquartered in Redwood City, California, has launched with an oversubscribed Series A financing totaling USD 77.5 million. The company is focused on developing therapies for chronic kidney disease, the lead program targeting hyperphosphatemia in dialysis patients. R1 acquired exclusive global rights outside of Greater China to that program - AP306, a pan phosphate transporter inhibitor - via a license deal with China-based Alebund Pharmaceuticals announced alongside the Series A. The round was co-led by Abingworth, F-Prime, and DaVita Venture Group, part of DaVita Inc. (NYSE: DVA), with participation from Curie.Bio, SymBiosis, and US Renal Care. The company said proceeds will fund a global development program for AP306, including a Phase IIb study planned to begin later this year. This is R1 Therapeutics' first disclosed funding round, coinciding with the company's formal launch. AP306, previously known as EOS789, was originally discovered by Chugai Pharmaceutical Co. and subsequently licensed to Alebund Pharmaceuticals, which conducted a Phase IIa study in hemodialysis patients in China. Results from that trial, published in Kidney International Reports, showed statistically significant reductions in serum phosphate with a tolerable safety profile. AP306 is described as the only clinical-stage agent that blocks active phosphate transport via three GI-tract transporters - NaPi-2b, PiT-1, and PiT-2 - distinguishing it from phosphate binders, which inhibit passive transport and have been the standard of care for six decades. More than 40% of US dialysis patients fail to reach phosphate targets with existing therapies, which carry high pill burden and GI tolerability issues, the company said. R1 is led by co-founder, president, and CEO Krishna Polu, M.D., a nephrologist with more than 20 years of biopharmaceutical experience. Co-founder L. Mary Smith, Ph.D., who previously served as chief development officer at SpringWorks Therapeutics, joins as chief operating officer. Your email address will not be published. Required fields are marked *

PharmiWeb
May 27th, 2025
Springworks Therapeutics Receives Positive Chmp Opinion For Mirdametinib For The Treatment Of Adult And Pediatric Patients With Nf1-Pn

SpringWorks Therapeutics Receives Positive CHMP Opinion for Mirdametinib for the Treatment of Adult and Pediatric Patients with NF1-PN. – If approved, mirdametinib is expected to be the first and only therapy in the European Union with marketing authorization for both adults and children with NF1-PN –. – Decision from European Commission expected in the third quarter of 2025 –

Merck Group
May 5th, 2025
agreement-to-acquire-springworks

Merck KGaA, Darmstadt, Germany, and SpringWorks Therapeutics, have entered into a definitive agreement for us to acquire SpringWorks.

MedCity News
Apr 28th, 2025
Merck KGaA's Rare Tumor Strategy Takes Shape With $3.9B SpringWorks Acquisition

When SpringWorks went public in 2019, the biotech priced its shares at $18 each.